|
KMID : 0363320220430030423
|
|
Journal of Korean Oriental Internal Medicine
2022 Volume.43 No. 3 p.423 ~ p.435
|
|
|
Clinical Effect of Gyeongok-go: A Systematic Review of Randomized Controlled Trials
|
|
Kang Hee-Kyung
Han Chang-Woo
|
|
|
Abstract
|
|
|
Purpose: The purpose of this study was to confirm the clinical efficacy of Gyeongok-go.
Methods: Public/Publisher MEDLINE (PubMed), Cochrane Central Register of Controlled Trials (CENTRAL), Excerpta Medica dataBASE (EMBASE), Research Information Sharing Service (RISS), ScienceON, Korean Traditional Knowledge Portal (KTKP), and China National Knowledge Infrastructure (CNKI) were searched for randomized controlled clinical trials administering Gyeongok-go as an intervention, published from inception to December 31, 2021. The risk-of-bias of the included trials was assessed with the Cochrane risk-of-bias tool for randomized trials version 2. From the experimental and control groups of the selected trials, the mean value (or rate) of each outcome was extracted and statistically compared.
Results: Statistically significant mean differences were in VO2max (MD 6.82), post-exercise heart rate (MD -8.76 at 5 min, -11.58 at 30 min, -14.6 at 60 min), senescence scale (MD -6.52), Th1 cells and Th2 cells in pulmonary tuberculosis (MD 2.79 and -1.64), yin-deficient and qi-deficient score (MD -9.64 and -9.76), and phlegm-dampness score (MD 5.56). Overall risk-of-bias was 20% low risk, 80% some concerns, and 0% high risk. There were no reports of adverse events.
Conclusions: Gyeongok-go is likely to have the effect of improving cardiorespiratory endurance, increasing fatigue recovery ability, reducing senescence, and enhancing immune function in tuberculosis patients. Also, it is more suitable for those who are yin-deficient or qi-deficient, and those with phlegm-dampness probably need caution.
|
|
|
KEYWORD
|
|
|
Gyeongok-go, clinical effect, systematic review
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
|
|